Activated Pharmaceutical Discovers Awake Hair Follicles: Could Signal End to Baldness, According to Researchers

In a groundbreaking discovery, a team of researchers led by biochemist Heather Christofk from UCLA, along with stem cell biologist Dr. William Lowry and chemist Michael Jung, have developed a new drug called PP405. This topical small molecule is set to revolutionize the treatment of hair loss, particularly for those suffering from chemotherapy-induced hair loss.

The drug works by activating hair follicle stem cells, promoting hair growth by inhibiting the mitochondrial pyruvate carrier (MPC), thereby shifting cellular metabolism towards glycolysis. This action directly affects the follicles' ability to grow hair, reactivating dormant hair follicles.

Intriguingly, the researchers found that hair follicle stem cells have a different metabolism when dormant compared to when they are actively growing hair. Specifically, they discovered that increasing lactate levels in sleeping hair-follicle stem cells might switch them on, leading to quicker hair growth.

To test this theory, the researchers used a molecule called UK-5099 to block the same pyruvate-moving protein in normal mice. The result was that these mice sprouted hair earlier than usual. When applied topically to the scalp, PP405 has already gone through two clinical trials to test its safety, with the safety trials having been completed.

The approach of PP405 is different from current treatments, which only slow down hair loss. This new drug promises to reactivate dormant follicles, potentially offering a more effective solution to hair loss.

The next clinical trial for PP405, set to begin next year, will test its effectiveness. The drug's action is confined to the scalp, reducing the likelihood of side effects.

The research behind PP405 was published in the prestigious journal "Nature Cell Biology". The project, however, has faced a setback with federal funding being cut by the Trump Administration. Despite this, Pelage Pharmaceuticals, founded by the researchers, is continuing its research on PP405.

Connie Chang, a freelance writer covering science, parenting, and health, reports on this development. As a recovering scientist, inveterate knitter, and fan fiction enthusiast, Chang brings a unique perspective to her work.

As the world awaits the results of the upcoming clinical trial, there is hope that PP405 could offer a promising solution for those struggling with hair loss.

Activated Pharmaceutical Discovers Awake Hair Follicles: Could Signal End to Baldness, According to Researchers